Heart Disease News and Research

Latest Heart Disease News and Research

Royal Philips Electronics, ACC to present Hybrid OR Suite designed for cardiac procedures at ACC 2010

Royal Philips Electronics, in partnership with the American College of Cardiology, spotlight the growing need for minimally-invasive interventions to address a spectrum of cardiac conditions, such as structural and degenerative heart issues. The need to reduce invasive surgical interventions and complication rates is driving innovations in minimally invasive approaches.

From Philips Healthcare 12 Mar 2010

Telemonitoring may reduce mortality of heart failure patients by 20%

Telemonitoring may reduce the mortality of patients with heart failure by 20%. Silke Schmidt et al. present their study results in the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[8]131-8).

12 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

Experts: Americans get too many tests, too much treatment

"Too much cancer screening, too many heart tests, too many cesarean sections. A spate of recent reports suggest that too many Americans -- maybe even President Barack Obama -- are being overtreated." Defensive medicine and a culture focusing on medical technology have lead to overtesting but "now new evidence and guidelines are recommending a step back and more thorough doctor-patient conversations about risks and benefits."

12 Mar 2010

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

St. Jude Medical, Inc. today announced it will display products and technologies from the company’s wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm management markets at ACC 2010.

12 Mar 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010

Cytori Therapeutics reports total revenues of $14.7M for 2009

Cytori Therapeutics is reporting its financial results for the year ended December 31, 2009.

From Evident Corporation - Life Sciences 12 Mar 2010

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

12 Mar 2010

LUMEDX announces latest addition to its CardioPACS imaging solution

LUMEDX, a leading provider of fully integrated cardiovascular information systems, announces the latest addition to its CardioPACS imaging solution: an interface to QLAB, proprietary ultrasound software from Philips. Through Philips’ QLAB advanced 2D and 3D ultrasound quantification tools within the LUMEDX CardioPACS application, facilities using Philips ultrasound systems can now enjoy greater efficiencies and enhanced accuracy of diagnosis.

12 Mar 2010

New micromanipulator for precise operations involving cochlear and middle ear implants

A team of engineers from the CEIT-IK4 technological centre and doctors from the University Hospital of Navarra have designed a new tool for operating on the inner ear with maximum precision, reducing the possibility of damage to the auditory function during the surgery. This is the first micromanipulator specifically for operations involving cochlear and middle ear implants, of which about a hundred are carried out in this hospital annually. Taking part in developing the new tool were four engineers from CEIT and five ear, nose and throat specialists from the University Hospital of Navarra.

12 Mar 2010

Study shows experimental thyroid drug reduces cholesterol

An experimental thyroid drug reduces cholesterol without the troublesome side effects experienced by some people on statins, according to a study published today in The New England Journal of Medicine. An international team of investigators at Johns Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for Medical Research tested a substance called Eprotirome in patients with high cholesterol.

12 Mar 2010

Growing incidence of chronic kidney disease: Early detection and knowledge of treatment options vital

As the incidence of diabetes and hypertension continues to grow worldwide – and increasing numbers of patients progressing to kidney disease and kidney failure place a financial strain on public health systems – the need for early patient education about kidney disease and treatment options, including home-based treatments, has become critical.

From Baxter International Inc. 12 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

High-intensity workout as effective as traditional types of exercise: study

The usual excuse of "lack of time" for not doing enough exercise is blown away by new research published in The Journal of Physiology.

12 Mar 2010

Minimally invasive surgical ablation for AFib: Unapproved, warns whistleblower

As reported in today's Wall Street Journal, the more than 2 million Americans with atrial fibrillation are now on notice that the over-zealous marketing tactics and incentives by manufacturers of expensive medical devices which are not approved by the U.S. Food and Drug Administration (FDA) for the treatment of atrial fibrillation are likely to be influencing doctors' and hospitals' decisions about treatment for their patients' heart conditions.

12 Mar 2010

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.

12 Mar 2010

Children with chronic illness more likely to develop H1N1 influenza: Study

As critical care professionals develop a better understanding of the progression of H1N1, they are becoming better prepared to treat children with severe cases, according to a new study that will be published in the March issue of Pediatric Critical Care Medicine (PCCM).

12 Mar 2010

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063.

12 Mar 2010

Hamilton Health Sciences establishes new research facility

Hamilton's role as one of the world's leading centres in cardiac, vascular and stroke research was amplified today with the grand opening of the David Braley Cardiac, Vascular and Stroke Research Institute at the Hamilton General Hospital site of Hamilton Health Sciences.

12 Mar 2010

Novel mutation in gene encoding ankyrin-B increases risk of type 2 diabetes

Alterations in our response to the taste or smell of food may be another culprit responsible for Type 2 diabetes, according to scientists at Duke University Medical Center who have identified the specific mechanism in human specimens and in mice.

12 Mar 2010

Heart Disease News and Research

Latest Heart Disease News and Research

Royal Philips Electronics, ACC to present Hybrid OR Suite designed for cardiac procedures at ACC 2010

Telemonitoring may reduce mortality of heart failure patients by 20%

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

Experts: Americans get too many tests, too much treatment

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

Cytori Therapeutics reports total revenues of $14.7M for 2009

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

LUMEDX announces latest addition to its CardioPACS imaging solution

New micromanipulator for precise operations involving cochlear and middle ear implants

Study shows experimental thyroid drug reduces cholesterol

Growing incidence of chronic kidney disease: Early detection and knowledge of treatment options vital

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

High-intensity workout as effective as traditional types of exercise: study

Minimally invasive surgical ablation for AFib: Unapproved, warns whistleblower

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

Children with chronic illness more likely to develop H1N1 influenza: Study

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

Hamilton Health Sciences establishes new research facility

Novel mutation in gene encoding ankyrin-B increases risk of type 2 diabetes

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Heart Disease News and Research

Latest Heart Disease News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in